Atlantic Health Strategies logo
LinkedIn icon
Contact Us

Atlantic Health Strategies

X-twitter Linkedin
Atlantic Health Strategies Logo

LifeStance Doubled EBITDA. Here’s What That Tells Operators About Payer Contracts and M&A Multiples.

Table of Contents

Ready to See Results?

From strategy through execution, Atlantic Health Strategies integrates compliance, operations, and growth into durable, measurable results. Let’s put our expertise to work for your organization.

Contact Us

What LifeStance's numbers actually tell operators

LifeStance Health Group (NASDAQ: LFST) posted roughly 94% year-over-year Adjusted EBITDA growth through 2024 and has kept compounding into 2025, driven by commercial payer rate increases, visit volume from clinician additions, and productivity gains. For outpatient behavioral health operators, that means two things: platform buyers are paying up for scaled, in-network outpatient assets with clean unit economics, and operators with clean data can push commercial payers harder on rate than they did two years ago.

Look at the disclosures. For full-year 2024, LifeStance grew revenue 19% to $1,251.0 million and Adjusted EBITDA to $119.7 million, roughly double the prior year’s $59.0 million. Ken Burdick, then Chairman and CEO, said “We grew revenue 19%, more than doubled Adjusted EBITDA, and generated strong Free Cash Flow of $86 million.” The company kept going. Full-year 2025 revenue reached $1,424.3 million and Adjusted EBITDA hit $157.7 million on 9.0 million visits across 8,040 clinicians.

The mechanism matters more than the headline. LifeStance’s own MD&A repeatedly credits total revenue per visit and clinician productivity, not just headcount growth. That is the playbook operators should read closely.

How rate, volume, and productivity actually stacked up

LifeStance Doubled EBITDA. Here's What That Tells Operators About Payer Contracts and M&A Multiples. — How rate, volume, and productivity actually stacked up

Breaking apart the EBITDA lift is the exercise smaller operators skip and later regret. Here is the shape of it from public filings.

Translate that for a 40-clinician outpatient group in Florida or Ohio. If you cannot show a payer your rate-per-visit trajectory, your visit-per-clinician-per-workday, your no-show rate, and your commercial mix by plan sponsor, you are negotiating blind against UnitedHealthcare, Optum, Elevance, Cigna’s Evernorth, or Aetna. LifeStance negotiates with the same carriers backed by a dashboard and a public-company earnings script. That is the asymmetry to close.

What this means for M&A: multiples, tuck-ins, and the sale process

The deal market followed the fundamentals. Capstone Partners reported behavioral healthcare sector dealmaking rose 47.1% year over year to 75 announced or closed transactions in the nine months ended September 30, 2025, with strategic acquirers up 105% versus a 9.7% uptick from financial buyers. Mertz Taggart counted 180 behavioral health transactions in 2025, up slightly from 176 in 2024, with lenders running “forensic” diligence on insurance receivables and cash collections. Mental health led activity; addiction treatment volume compressed.

For AHS clients on either side of a transaction, three practical implications:

  1. Sellers can defend valuation with LFST comps, but only with the receipts. A buyer’s IOI will assume your rate curve is flat unless you can prove year-over-year rate increases by payer and CPT. Pull the data. Reconcile it to 835s. Bring it to the process.
  2. Tuck-ins remain accretive when the target is truly in-network. A solo psychiatry practice with weak commercial contracts loaded onto a platform’s fee schedule can lift blended rate immediately. If the contracts do not assign, the accretion evaporates.
  3. Federal Trade Commission and Hart-Scott-Rodino sensitivity is real. Regulators have visibly increased scrutiny of private-equity roll-up strategies in healthcare, which is one reason many deals stopped announcing publicly this year.

None of this is theoretical. On the compliance side, our team was on site in South Carolina in May 2026 when a client’s Joint Commission survey closed early with high praise from the surveyor, and separately, five facilities across three states earned three-year Joint Commission accreditation the same month. Accredited, in-network, multi-site: that is the profile getting the premium multiple.

MHPAEA, the CMS IBH Model, and the ground that shifted underneath everyone

Two federal moves reshaped the negotiating table in the last 18 months, and operators are still mispricing them.

First, the Mental Health Parity and Addiction Equity Act. The Departments of Labor, Health and Human Services, and Treasury issued a 2024 final rule strengthening comparative analyses of non-quantitative treatment limitations. Then on January 17, 2025 the ERISA Industry Committee sued to block the rule, and on May 12, 2025 the Departments announced a non-enforcement policy for portions of the NQTL final regulation pending reconsideration, while MHPAEA enforcement remains a stated 2026 DOL priority. Translation for operators: DOL EBSA is not rescinding parity. They are pausing one rule while continuing to open investigations. If your prior-authorization data, denial patterns, and network-adequacy documentation are organized, you still have a parity argument to bring into a rate negotiation.

Second, CMS launched the Innovation in Behavioral Health (IBH) Model. Cohort 1 awards on January 1, 2025 went to Michigan and South Carolina, among others. If you operate in an IBH state, your Medicaid mix conversation with a buyer looks different than it did 24 months ago. Model this in the pro forma before a sponsor does it for you.

LifeStance Doubled EBITDA. Here's What That Tells Operators About Payer Contracts and M&A Multiples. — MHPAEA, the CMS IBH Model, and the ground that shifted underneath everyone

Frequently asked questions

What EV/EBITDA multiples are outpatient behavioral health platforms trading at right now?
Public comparables are noisy. LFST was trading at an EV/EBITDA multiple of 68.4x on a trailing basis after its Q1 2025 print, which reflects growth expectations more than a normalized comp. Private outpatient platforms with real scale and clean commercial mix have been transacting in a wide band; smaller tuck-ins are meaningfully lower. Anchor to your own quality of earnings, not a screenshot.

How much of LifeStance’s EBITDA growth came from rate versus volume?
Both, with rate leading margin expansion and volume driving absolute dollars. Q1 2024 EBITDA growth of 174% was disproportionately rate-driven. By 2025, productivity (visits per clinician workday) became the third leg. Smaller operators can rarely move all three at once; pick the one with the shortest cycle time.

What should I benchmark before asking UnitedHealthcare, Cigna, or Aetna for a rate increase?
Rate per visit trend by CPT and by payer, visit volume and no-show rate, clinician productivity, days in AR, denial rate, appeals win rate, and network adequacy data. If you cannot generate those six metrics reliably, fix the reporting before you send the letter.

Are tuck-in acquisitions of solo and small-group practices still accretive?
Yes, when contract assignment is clean, credentialing gaps are short, and the target is in-network with the platform’s top three payers. No, when the target is out-of-network and the platform is buying the roster hoping to re-contract later.

How does MHPAEA enforcement change my position in commercial payer negotiations?
Even under the current non-enforcement posture on the NQTL final rule, DOL EBSA continues to investigate. Documented disparities in prior authorization, session limits, and network adequacy remain a legitimate argument in a rate conversation. Build the file before you need it.

References

Request a Free Consultation

Scroll to Top